New York-based Bristol-Myers Squibb Co. has announced a definitive agreement to purchase Wilmington, DE-based DuPont Pharmaceuticals Co. Bristol-Myers Squibb hopes the acquisition will further strengthen the company's medicines business.
New York-based Bristol-Myers Squibb Co. has announced a definitive agreement to purchase Wilmington, DE-based DuPont Pharmaceuticals Co. Bristol-Myers Squibb hopes the acquisition will further strengthen the company's medicines business.
"This acquisition is an important step in aggressively implementing our growth strategy, which envisions expanding our medicines business through acquisitions, joint ventures, licensing and co-promotion agreements, as well as through our own intensive and productive research and development efforts," said Peter R. Dolan, president and chief executive officer of Bristol-Myers Squibb.
Under the terms of the agreement, Bristol-Myers Squibb will pay $7.8 billion in cash for DuPont Pharmaceuticals. Subject to approval by appropriate regulatory agencies and customary closing conditions, the transaction should be completed by the end of the year. Last year, DuPont Pharmaceuticals realized sales of $1.5 billion.
"DuPont Pharmaceuticals is a valuable company that will bring significant additional value to Bristol-Myers Squibb," said Dolan. "It has outstanding people as well as great products that will add to our strong virology and cardiovascular franchises. Several of the promising compounds in its research and development pipeline have novel mechanisms of action and blockbuster potential. They have the potential to address serious unmet medical needs, and contribute to the acceleration of our pharmaceutical sales and earnings growth in the future." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.